Table 2. Rate of Alcohol-Related Events Associated With OUD Medications, Stratified by Recent AUD Claimsa.
| Variable | Total (N = 8 424 214 person-days among 13 335 individuals) | OUD with recent AUD claims (n = 4 629 076 person-days among 7462 individuals) | OUD without recent AUD claims (n = 3 795 138 person-days among 5873 individuals) | |||
|---|---|---|---|---|---|---|
| Mean d/person, No. | Rate of alcohol-related events/100 d | Mean d/person, No. | Rate of alcohol-related events/100 d | Mean d/person, No. | Rate of alcohol-related events/100 d | |
| Treatment | ||||||
| Buprenorphine | 62.7 | 0.15 | 48.9 | 0.13 | 80.3 | 0.16 |
| Methadone | 8.4 | 0.11 | 5.8 | 0.11 | 11.7 | 0.12 |
| Naltrexone extended-release | 6.4 | 0.19 | 7.5 | 0.20 | 5.1 | 0.18 |
| Naltrexone oral | 15.7 | 0.29 | 21.5 | 0.29 | 8.2 | 0.28 |
| Nonmedication | 535.0 | 0.22 | 534.6 | 0.25 | 535.6 | 0.18 |
| All observation days | 627.6 | 0.21 | 617.5 | 0.24 | 640.4 | 0.18 |
Abbreviations: AUD, alcohol use disorder; OUD, opioid use disorder.
a
This table depicts the percentage of insurance coverage days entailing an alcohol-related acute event, which is compared among days when participants were receiving buprenorphine, methadone, naltrexone (extended release or oral), and nonmedication treatment days. These analyses were further stratified between persons who had recent AUD claims and those without recent AUD claims.